Last reviewed · How we verify
NCT06096688
Discovering New Targets for Colorectal and Endometrial Cancer Risk Reduction
trial in Colorectal Cancer in 1,120 participants. Currently enrolling.
29 May 2026
Quick facts
| Lead sponsor | Weill Medical College of Cornell University |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 1,120 |
| Start date | 29 May 2019 |
| Primary completion | 29 May 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 1 location across United States |
Conditions studied
- Colorectal Cancer — all drugs for Colorectal Cancer →
- Endometrial Cancer — all drugs for Endometrial Cancer →
- Hereditary Cancer Syndromes — all drugs for Hereditary Cancer Syndromes →
Sponsor
Weill Medical College of Cornell University
Who can join
18 and older, any sex, with Colorectal Cancer or Endometrial Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary aim of this study is to collect and store data, tissue, and personal and family histories from patients being screened for colorectal cancer and/or endometrial cancer at NYPH and WCM for routine clinical care and to make these available for future use for molecular and mechanistic studies.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Colorectal cancer chemoprevention: Exploring the path from molecular mechanisms to available drugs.
Ivy DM, Bordone R, Di Magno L, Coni S, et al · · 2025 · PMID 40907725 · DOI 10.1016/j.bbcan.2025.189439
Verify or expand the search:
- PubMed search for NCT06096688
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Colorectal Cancer
Currently open trials in the same condition.
- NCT07152821 — Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino · Phase 3 · recruiting
- NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
- NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
- NCT07523919 — Functional and Respiratory Determinants of Long-Term Colorectal Cancer Outcomes · recruiting
- NCT07529301 — Functional and Respiratory Predictors of Early Postoperative Outcomes · recruiting
Other Weill Medical College of Cornell University trials
Trials by the same sponsor.
- NCT07485712 — Center for Research and Education on Aging and Technology Enhancement - CREATE V - Project 2 · NA · not yet recruiting
- NCT05811338 — Center for Research and Education on Aging and Technology Enhancement - CREATE V - Project 1 · NA · not yet recruiting
- NCT06118983 — Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF) · NA · recruiting
- NCT06818734 — Implementation of a Clinical Decision Support Tool for Postpartum Depression · NA · not yet recruiting
- NCT07485725 — Center for Research and Education on Aging and Technology Enhancement - CREATE V - Project 3 · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06096688 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Weill Medical College of Cornell University
- Last refreshed: 4 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06096688.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing